|
| Title |
|
|
|
Importance of secondary screening with clinical isolates for anti-leishmania drug discovery
| |
| Author |
|
|
|
| |
| Abstract |
|
|
| | |
| Language |
|
|
|
English
| |
| Source (journal) |
|
|
|
Scientific reports. - London, 2011, currens | |
| Publication |
|
|
|
London : Nature Publishing Group, 2018
| |
| ISSN |
|
|
|
2045-2322
| |
| Volume/pages |
|
|
|
8(2018), 13 p.
| |
| Article Reference |
|
|
|
11765
| |
| ISI |
|
|
|
000440782000052
| |
| Pubmed ID |
|
|
|
30082744
| |
| Medium |
|
|
|
E-only publicatie
| |
| Full text (Publisher's DOI) |
|
|
| | |
| Full text (open access) |
|
|
| | |
|
| Faculty/Department |
|
|
| | |
| Research group |
|
|
|
| Project info |
|
|
|
EUROLEISH-NET: Control of leishmaniasis, from bench to bedside and community Targeting host-encoded factors for anti-leishmania therapy? Insights from chemical genetics and antimony resistant field isolates.
| Publication type |
|
|
| | | |
| Subject |
|
|
| | | |
| Affiliation |
|
|
|
Publications with a UAntwerp address
| |
|
|
|
| Identification |
|
| |
|
|
| Creation |
|
| |
07.09.2018
|
|
| Last edited |
|
| |
12.10.2020
|
|
| To cite this reference |
|
|
| | |
|
| |